Project Grant W911NF2510072

This is a Project Grant Award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award provides $629,556 to Vanderbilt University Medical Center (VUMC) to research the mechanisms by which human milk-derived oligosaccharides, specifically 2'-fucosyllactose (2'-FL), can protect the intestinal barrier and attenuate inflammation. The key products and services to be...

This federal Project Grant award from the National Center for Complementary and Integrative Health (NCCIH), under the Research and Training in Complementary and Integrative Health program (CFDA 93.213), provides $506,000 to the Scripps Research Institute to develop orally available recombinant peptidoglycan hydrolase therapeutics to promote intestinal barrier function and protect against enteric pathogens. The key objectives are to evaluate the activity of recombinant Enterococcus...

The University of California, Davis was awarded a $596,150 Project Grant from the United States Department of Agriculture's National Institute of Food and Agriculture to develop novel food-grade materials and formulations containing probiotics. The three-year grant, awarded under the Agriculture and Food Research Initiative competitive grants program, aims to address challenges to the viability and persistence of probiotics during digestion and in the gut by creating bioengineered...

The University of Arizona was awarded a $180,000 Project Grant from the United States Department of Agriculture's National Institute of Food and Agriculture under the Agriculture and Food Research Initiative competitive grants program. The three-year award beginning June 1, 2023 will support research examining how shifts in the small intestinal microbiota following oligofructose supplementation can improve glucose homeostasis and help address metabolic diseases like obesity and type 2...

This $195,213 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to investigate the mechanisms by which the gut microbiota uses short-chain fatty acids, particularly propionate, to inhibit the growth of the enteric pathogen Yersinia enterocolitica. The research team at the University of California, Davis will pursue two specific aims: 1) determining the mechanism of...

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, provides $325,139 in funding for a feasibility and proof-of-concept study on using targeted polyclonal antibodies to neutralize bioactive molecules in the gut microbiomes of individuals with microbiome-driven inflammation and loss of gut barrier function. The key products and services to be delivered through this award include: 1) Determining the impact of six...

This Project Grant award of $122,786 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports scientific research focused on understanding the mechanisms by which the gut bacterium Phocaeicola vulgatus (PVu) colonizes and competes within the mammalian gut microbiome. The research aims to define the specific genetic and molecular functions that enable PVu to effectively infiltrate and persist in established gut microbial...

This $663,173 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to leverage glycan-metabolite interactions to shape the structure and function of the gut microbiome. The key objectives are to: 1) Define the impact of butyrate on the composition of the Bacteroides genus within the gut microbiome in vivo, 2) Determine the role of the...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $450,862 to the University of Chicago to investigate the immunomodulatory effects of a bacterial-derived secondary bile acid called isodeoxycholic acid (isoDCA). The researchers will create a two-strain engineered consortium of gut bacteria to toggle isoDCA production on and off, enabling them to study how this...

This five-year, $2.5 million Project Grant from the National Science Foundation's Biological Sciences program (CFDA 47.074) supports research at Stanford University to systematically dissect complex synthetic gut bacterial communities. Principal Investigator Dr. Lance Palmer and collaborators at the University of California, Berkeley will develop an integrated model spanning molecular to community levels focusing on corrinoid metabolites. They will synthesize gut-relevant corrinoids and...